PDCD1 and non-Hodgkin lymphoma: These tumors, in comparison to other types of NHL, have high expression of PD1, PD-L1, and/or PD-L2, which forms the basis for CPI in these conditions, and therapeutic responses have been seen in these diseases in early phase clinical trials.